20 reports

By the year 2040, ## adult in ## will have diabetes.

  • Insulin Delivery
  • Type 1 Diabetes
  • World
  • Market Size
  • Animas Corporation
  • Pipeline analysis

Sotagliflozin is a small molecule and exhibits its mechanism by inhibiting SGLT-##, which helps absorb glucose and galactose in the gastrointestinal (GI) tract, and SGLT-##, which helps in glucose reabsorption by the kidney.

  • Type 1 Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

NIHS' research categories comprise brain health, molecular nutrition, system science, cell biology, mitochondrial function, omics, informatics, cognitive health and ageing, metabolic health, and gastrointestinal health.

  • Cell Therapy
  • Type 1 Diabetes
  • United States
  • Company Operations
  • ViaCyte, Inc.
  • 06/05/2017: Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions
  • Sep 05, 2017: Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting

Most carcinoid tumors are found in the gastrointestinal tract.

  • Pharmaceutical
  • Therapy
  • Type 1 Diabetes
  • United States
  • Lexicon Pharmaceuticals, Inc.
  • SYNTHETIC PEPTIDE TO AGONIZE NK1 FOR TYPE 1 DIABETES - DRUG PROFILE
  • COMPUGEN LTD

Its pipeline candidates are used to treat the gastrointestinal and CRC and orphan diseases.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Company

BioChaperone Glargine GLP-##, ##-in-## combinations of basal insulin glargine and GLP-## receptor agonists: BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide.

  • Healthcare
  • Type 1 Diabetes
  • France
  • Company
  • Adocia

Participants were allocated ##:##:##:## to receive daily infusions of teplizumab (full dose for ## days, ##/ ## dose for ## days, or full dose for six days) or placebo at baseline and at six months.

  • Therapy
  • Type 1 Diabetes
  • United States
  • World
  • Product Initiative

Inflammatory bowel disease (IBD) is one of the most functional gastrointestinal disorders, caused due to abnormal immune response.

  • Immunochemistry Test
  • Type 1 Diabetes
  • World
  • Market Size
  • Thermo Fisher Scientific, Inc.
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY REGIMMUNE CORPORATION, H2 2016
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY CARLINA TECHNOLOGIES SAS, H2 2016

It discovers, develops and commercializes medicines for gastrointestinal disorders.

  • Biotechnology
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Company
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Endocrine Disease
  • Type 1 Diabetes
  • World
  • Product Initiative
  • Type 1 Diabetes
  • Telotristatetiprate (LX1032)

SGLT## is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract.

  • Clinical Trial
  • Endocrine Disease
  • Pharmaceutical
  • Therapy
  • Type 1 Diabetes

The molecules developed by companies in Phase III, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Therapy
  • Type 1 Diabetes
  • World
  • Product Initiative
  • Shenogen Pharma Group
  • PIPELINE BY GLAXOSMITHKLINE PLC, H1 2016

The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders.

  • Glycoprotein
  • Type 1 Diabetes
  • World
  • Product Initiative
  • Xencor, Inc.
  • Mar 08, 2018: Unique inflammation patterns emerging in patients with type 1 diabetes

Potential applications include hearing loss, skin disorders and gastrointestinal diseases.

  • Diabetes
  • Healthcare
  • Pharmaceutical
  • Type 1 Diabetes
  • United States
  • Clinical Trial Profile Snapshots

Glucagon-like peptide - ## (GLP-##) is a gastrointestinal hormone that is released postprandially (after meals) from the intestinal L-cells, which binds to GLP-## receptors on the beta cells of the pancreas and causes insulin release.

  • Clinical Trial
  • Drug Discovery And Development
  • Type 1 Diabetes
  • World
  • Product Initiative